Using Healthcare Claims Data to Analyze the Prevalence of Chronic Myeloid Leukemia in France: A Nationwide Population-Based Study

Conclusion: Healthcare claims data are increasingly used to estimate epidemiological parameters worldwide. This approach is particularly relevant for rare diseases and administrative databases with high population coverage. Countries without national cohorts or cancer registries could easily use our algorithm to estimate their prevalence of CML.DisclosuresCony-Makhoul: Pfizer: Consultancy; BMS: Consultancy, Speakers Bureau; Incyte: Other: Travels for attending to Congress; Novartis: Consultancy, Other: Writing support, Travels for attending to Congress. Guerci-Bresler: Pfizer: Other: Fees for symposiums and boards; Novartis: Consultancy, Other: Fees for symposiums and boards; Incyte: Other: Fees for symposiums and boards; BMS: Other: Fees for symposiums and boards; Pfizer: Other: Travel fees for Congress. Delord: Incyte: Consultancy.

Source: Blood - November 21, 2018 Category: Hematology Authors: Foulon, S., Cony-Makhoul, P., Guerci-Bresler, A., Delord, M., Solary, E., Monnereau, A., Bonastre, J., Tubert Bitter, P. Tags: 632. Chronic Myeloid Leukemia: Therapy: Poster II Source Type: research